Literature DB >> 30640367

Assessment of Spending in Medicare Part D If Medication Prices From the Department of Veterans Affairs Were Used.

Brett Venker1, Kevin B Stephenson2, Walid F Gellad3,4.   

Abstract

Mesh：

Year:  2019        PMID： 30640367      PMCID： PMC6439699          DOI： 10.1001/jamainternmed.2018.5874

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  8 in total

1.  Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.

Authors:  Natalie McCormick; Zachary S Wallace; Chana A Sacks; John Hsu; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2020-01-06       Impact factor: 10.995

2.  Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.

Authors:  Michael Liu; Brian MacKenna; William B Feldman; Alex J Walker; Jerry Avorn; Aaron S Kesselheim; Ben Goldacre
Journal:  J R Soc Med       Date:  2020-09       Impact factor: 5.344

3.  Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.

Authors:  William B Feldman; Benjamin N Rome; Lisa Soleymani Lehmann; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2020-04-01       Impact factor: 21.873

4.  Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary.

Authors:  William B Feldman; Jerry Avorn; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2020-03-01       Impact factor: 21.873

5.  The high cost of prescription drugs: causes and solutions.

Authors:  S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2020-06-23       Impact factor: 11.037

6.  Medication Shortages During the COVID-19 Crisis: What We Must Do.

Authors:  Esther K Choo; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2020-04-03       Impact factor: 7.616

7.  Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.

Authors:  Paweł Żelewski; Michał Wojna; Katarzyna Sygit; Elżbieta Cipora; Izabela Gąska; Mateusz Niemiec; Mateusz Kaczmarski; Tomasz Banaś; Beata Karakiewicz; Artur Kotwas; Paulina Zabielska; Olga Partyka; Monika Pajewska; Edyta Krzych-Fałta; Ewa Bandurska; Weronika Ciećko; Aleksandra Czerw
Journal:  Int J Environ Res Public Health       Date:  2022-09-24       Impact factor: 4.614

8.  Older Americans' Preferences Between Lower Drug Prices and Prescription Drug Plan Choice, 2019.

Authors:  Mariana P Socal; Gerard F Anderson
Journal:  Am J Public Health       Date:  2020-01-16       Impact factor: 9.308
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.